Review



anti timp3 antibody  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Santa Cruz Biotechnology anti timp3 antibody
    Anti Timp3 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 124 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/timp3+antibody/TIMP-3+Antibody/pmc12849824-34-8-11
    Average 94 stars, based on 124 article reviews
    anti timp3 antibody - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Expressing:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Western Blot:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Staining:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Control:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Infection:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Reverse Transcription Polymerase Chain Reaction:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Transfection:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Activity Assay:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Zymography Assay:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Virus:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Migration:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Tube Formation Assay:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Injection:

    Article Title: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
    Article Snippet: The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).



    Similar Products

    94
    Santa Cruz Biotechnology anti timp3 antibody
    Anti Timp3 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/timp3+antibody/TIMP-3+Antibody/pmc12849824-34-8-11
    Average 94 stars, based on 1 article reviews
    anti timp3 antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    Proteintech timp3
    Whole exome sequencing. ( A ) Sanger sequencing chromatograms of twelve family members identified the heterozygous c.572A>G (p. Y191C ) <t>TIMP3</t> variant in the proband (III:5), his father (II:6), uncle (II:3, II:8), aunt (II:11), and cousins (III:3, III:10). ( B ) Pedigree analysis illustrating the inheritance of the c.572A>G (p. Y191C ) variant. ( C ) Multiple sequence alignments of TIMP3 Tyr191 across species revealed that the variant occurred in highly conserved residues. ( D ) Schematic structures of the original and mutant amino acids, highlighting the backbone in red and the side chain in black. ( E ) Comparative 3D structures of the wild-type ( a ) and mutant ( b ) proteins.
    Timp3, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/timp3+antibody/Timp-3+Antibody/pmc12701730-77-3-4
    Average 93 stars, based on 1 article reviews
    timp3 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology timp3
    Whole exome sequencing. ( A ) Sanger sequencing chromatograms of twelve family members identified the heterozygous c.572A>G (p. Y191C ) <t>TIMP3</t> variant in the proband (III:5), his father (II:6), uncle (II:3, II:8), aunt (II:11), and cousins (III:3, III:10). ( B ) Pedigree analysis illustrating the inheritance of the c.572A>G (p. Y191C ) variant. ( C ) Multiple sequence alignments of TIMP3 Tyr191 across species revealed that the variant occurred in highly conserved residues. ( D ) Schematic structures of the original and mutant amino acids, highlighting the backbone in red and the side chain in black. ( E ) Comparative 3D structures of the wild-type ( a ) and mutant ( b ) proteins.
    Timp3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/timp3+antibody/TIMP-3+Antibody/pm41067282-105-20-44
    Average 94 stars, based on 1 article reviews
    timp3 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    Biorbyt human hmgb1 enzymelinked immunosorbent assay elisa kit
    Whole exome sequencing. ( A ) Sanger sequencing chromatograms of twelve family members identified the heterozygous c.572A>G (p. Y191C ) <t>TIMP3</t> variant in the proband (III:5), his father (II:6), uncle (II:3, II:8), aunt (II:11), and cousins (III:3, III:10). ( B ) Pedigree analysis illustrating the inheritance of the c.572A>G (p. Y191C ) variant. ( C ) Multiple sequence alignments of TIMP3 Tyr191 across species revealed that the variant occurred in highly conserved residues. ( D ) Schematic structures of the original and mutant amino acids, highlighting the backbone in red and the side chain in black. ( E ) Comparative 3D structures of the wild-type ( a ) and mutant ( b ) proteins.
    Human Hmgb1 Enzymelinked Immunosorbent Assay Elisa Kit, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/timp3+antibody/TIMP3+antibody/pm40685578-170-6-14
    Average 93 stars, based on 1 article reviews
    human hmgb1 enzymelinked immunosorbent assay elisa kit - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    90
    Millipore timp3 mab3318 antibody
    Whole exome sequencing. ( A ) Sanger sequencing chromatograms of twelve family members identified the heterozygous c.572A>G (p. Y191C ) <t>TIMP3</t> variant in the proband (III:5), his father (II:6), uncle (II:3, II:8), aunt (II:11), and cousins (III:3, III:10). ( B ) Pedigree analysis illustrating the inheritance of the c.572A>G (p. Y191C ) variant. ( C ) Multiple sequence alignments of TIMP3 Tyr191 across species revealed that the variant occurred in highly conserved residues. ( D ) Schematic structures of the original and mutant amino acids, highlighting the backbone in red and the side chain in black. ( E ) Comparative 3D structures of the wild-type ( a ) and mutant ( b ) proteins.
    Timp3 Mab3318 Antibody, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/timp3+antibody/timp+3+antibody/pmc12090231-7-4-2
    Average 90 stars, based on 1 article reviews
    timp3 mab3318 antibody - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    Whole exome sequencing. ( A ) Sanger sequencing chromatograms of twelve family members identified the heterozygous c.572A>G (p. Y191C ) TIMP3 variant in the proband (III:5), his father (II:6), uncle (II:3, II:8), aunt (II:11), and cousins (III:3, III:10). ( B ) Pedigree analysis illustrating the inheritance of the c.572A>G (p. Y191C ) variant. ( C ) Multiple sequence alignments of TIMP3 Tyr191 across species revealed that the variant occurred in highly conserved residues. ( D ) Schematic structures of the original and mutant amino acids, highlighting the backbone in red and the side chain in black. ( E ) Comparative 3D structures of the wild-type ( a ) and mutant ( b ) proteins.

    Journal: Clinical Ophthalmology (Auckland, N.Z.)

    Article Title: Sorsby Fundus Dystrophy in an Asian Pedigree: Pathogenic Timp3 P.Y191c Variant Impairs Its Binding with Mmp2/9 and Cellular Localization

    doi: 10.2147/OPTH.S556592

    Figure Lengend Snippet: Whole exome sequencing. ( A ) Sanger sequencing chromatograms of twelve family members identified the heterozygous c.572A>G (p. Y191C ) TIMP3 variant in the proband (III:5), his father (II:6), uncle (II:3, II:8), aunt (II:11), and cousins (III:3, III:10). ( B ) Pedigree analysis illustrating the inheritance of the c.572A>G (p. Y191C ) variant. ( C ) Multiple sequence alignments of TIMP3 Tyr191 across species revealed that the variant occurred in highly conserved residues. ( D ) Schematic structures of the original and mutant amino acids, highlighting the backbone in red and the side chain in black. ( E ) Comparative 3D structures of the wild-type ( a ) and mutant ( b ) proteins.

    Article Snippet: Primary antibodies included TIMP3 (Proteintech, 10858-1-AP, WB: 1:2000, IP: 1:1000, IF: 1:400), MMP9 (Proteintech, 10375-2-AP, WB: 1:600, IP:1:500, IF: 1:100), MMP2 (Proteintech, 66366-1-Ig, WB: 1:1000, IP:1:500, IF: 1:200), and GAPDH (Abcam, ab8245, 1:5000).

    Techniques: Sequencing, Variant Assay, Mutagenesis

    The TIMP3 variant Y191C mitigated the cell viability and promoted the apoptosis of ARPE-19. ( A ) CCK-8 assay demonstrated a significant reduction in cell viability in the MT group compared to the empty vector control group 24 hours post-LPS treatment ( P= 0.0096), while no significant difference was observed in the WT group ( P= 0.7128). ( B and C ) Flow cytometry analysis indicated a significant increase in apoptosis rates in the MT group compared to the empty vector control group following LPS treatment ( P= 0.0005). In contrast, the WT group exhibited a 10% reduction in apoptosis rates compared to the empty vector control group. FIGURE 4 The TIMP3 variant Y191C mitigated the cell viability and promoted the apoptosis of ARPE-19. ( A ) CCK-8 assay demonstrated a significant reduction in cell viability in the MT group compared to the empty vector control group 24 hours post-LPS treatment ( P= 0.0096), while no significant difference was observed in the WT group ( P= 0.7128). ( B and C ) Flow cytometry analysis indicated a significant increase in apoptosis rates in the MT group compared to the empty vector control group following LPS treatment ( P= 0.0005). In contrast, the WT group exhibited a 10% reduction in apoptosis rates compared to the empty vector control group. n=3/group. “n” denotes biological replicates, defined as independently assayed aliquots derived from the same lentiviral infection and differentiation batch.

    Journal: Clinical Ophthalmology (Auckland, N.Z.)

    Article Title: Sorsby Fundus Dystrophy in an Asian Pedigree: Pathogenic Timp3 P.Y191c Variant Impairs Its Binding with Mmp2/9 and Cellular Localization

    doi: 10.2147/OPTH.S556592

    Figure Lengend Snippet: The TIMP3 variant Y191C mitigated the cell viability and promoted the apoptosis of ARPE-19. ( A ) CCK-8 assay demonstrated a significant reduction in cell viability in the MT group compared to the empty vector control group 24 hours post-LPS treatment ( P= 0.0096), while no significant difference was observed in the WT group ( P= 0.7128). ( B and C ) Flow cytometry analysis indicated a significant increase in apoptosis rates in the MT group compared to the empty vector control group following LPS treatment ( P= 0.0005). In contrast, the WT group exhibited a 10% reduction in apoptosis rates compared to the empty vector control group. FIGURE 4 The TIMP3 variant Y191C mitigated the cell viability and promoted the apoptosis of ARPE-19. ( A ) CCK-8 assay demonstrated a significant reduction in cell viability in the MT group compared to the empty vector control group 24 hours post-LPS treatment ( P= 0.0096), while no significant difference was observed in the WT group ( P= 0.7128). ( B and C ) Flow cytometry analysis indicated a significant increase in apoptosis rates in the MT group compared to the empty vector control group following LPS treatment ( P= 0.0005). In contrast, the WT group exhibited a 10% reduction in apoptosis rates compared to the empty vector control group. n=3/group. “n” denotes biological replicates, defined as independently assayed aliquots derived from the same lentiviral infection and differentiation batch.

    Article Snippet: Primary antibodies included TIMP3 (Proteintech, 10858-1-AP, WB: 1:2000, IP: 1:1000, IF: 1:400), MMP9 (Proteintech, 10375-2-AP, WB: 1:600, IP:1:500, IF: 1:100), MMP2 (Proteintech, 66366-1-Ig, WB: 1:1000, IP:1:500, IF: 1:200), and GAPDH (Abcam, ab8245, 1:5000).

    Techniques: Variant Assay, CCK-8 Assay, Plasmid Preparation, Control, Flow Cytometry, Derivative Assay, Infection

    The Y191C variant inhibited the interaction between TIMP3 and MMP proteins. ( A and B ) The Y191C mutation increases FLAG-TIMP3 complex formation, selectively enhancing interaction with MMP9 proteolytic fragments (45~55 kDa) while reducing MMP2 binding. ( C – E ) Following LPS administration, MMP2 expression levels in the empty vector control group remained comparable to those in the normal control group. However, in the MT group, MMP2 expression was significantly elevated compared to the empty vector group ( P < 0.0001, 1.84 ± 0.21-fold) and showed a modest increase compared to the WT control group ( P= 0.0889, 1.15 ± 0.13-fold). Additionally, MMP9 expression in the MT group was markedly higher than in the empty vector group after LPS treatment ( P < 0.0172, 2.12 ± 0.41-fold). ( F ) IF staining revealed nuclear localization of MMP2 in ARPE-19 cells of the WT group, whereas in the MT group, MMP2 expression extended into the cytoplasm of ARPE-19 cells. n=3/group. “n” refers to the number of independent biological replicates.

    Journal: Clinical Ophthalmology (Auckland, N.Z.)

    Article Title: Sorsby Fundus Dystrophy in an Asian Pedigree: Pathogenic Timp3 P.Y191c Variant Impairs Its Binding with Mmp2/9 and Cellular Localization

    doi: 10.2147/OPTH.S556592

    Figure Lengend Snippet: The Y191C variant inhibited the interaction between TIMP3 and MMP proteins. ( A and B ) The Y191C mutation increases FLAG-TIMP3 complex formation, selectively enhancing interaction with MMP9 proteolytic fragments (45~55 kDa) while reducing MMP2 binding. ( C – E ) Following LPS administration, MMP2 expression levels in the empty vector control group remained comparable to those in the normal control group. However, in the MT group, MMP2 expression was significantly elevated compared to the empty vector group ( P < 0.0001, 1.84 ± 0.21-fold) and showed a modest increase compared to the WT control group ( P= 0.0889, 1.15 ± 0.13-fold). Additionally, MMP9 expression in the MT group was markedly higher than in the empty vector group after LPS treatment ( P < 0.0172, 2.12 ± 0.41-fold). ( F ) IF staining revealed nuclear localization of MMP2 in ARPE-19 cells of the WT group, whereas in the MT group, MMP2 expression extended into the cytoplasm of ARPE-19 cells. n=3/group. “n” refers to the number of independent biological replicates.

    Article Snippet: Primary antibodies included TIMP3 (Proteintech, 10858-1-AP, WB: 1:2000, IP: 1:1000, IF: 1:400), MMP9 (Proteintech, 10375-2-AP, WB: 1:600, IP:1:500, IF: 1:100), MMP2 (Proteintech, 66366-1-Ig, WB: 1:1000, IP:1:500, IF: 1:200), and GAPDH (Abcam, ab8245, 1:5000).

    Techniques: Variant Assay, Mutagenesis, Binding Assay, Expressing, Plasmid Preparation, Control, Staining